LGND News and Press, Ligand Pharmaceuticals Incorporated From 07/08/20

Eli Lilly ( LLY +1.3% ) will collaborate with privately held Sermonix in an open-label Phase 2 clinical trial, ELAINE 2 , evaluating the combination of Verzenio (abemaciclib) and the latter's lead drug lasofoxifene in pre- and postmenopausal women with locally advanced/metastatic ER+/HE...

COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced a collaboration with Eli Lilly and Com...

The Federal Reserve's financial stress test results increase risk of credit tightening and dividend cuts, and that should make most investors uneasy about buying banks. Fiscal and monetary policy could ease the burden of rising delinquency and default rates resulting from job losses and slower...

Investment Thesis Ligand Pharmaceuticals 1-year share price performance. Source: TradingView Before the market sell-off at the end of last week Ligand Pharmaceuticals' (NASDAQ: LGND ) stock had been buoyant, trading at $124 - its highest price since April 2019. The company delivered a ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical company based in France, to jointly identify and enable new therapeutic targets. The new ...

Have you ever found yourself saying a stock is too expensive because it's made a big move in a short period of time? Or that a stock is too cheap to ignore because its price has fallen sharply? Anchoring bias, or the tendency to fixate on a past price when considering a new investment idea, ca...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The full text of that letter is as follows: To Our Valued Captisol Customers, Ligand is in a period of momentous planni...

Deals and Financings MGI Tech of Shenzhen, a company making gene-sequencing machines and related equipment, completed a $1 billion Series B round led by IDG Capital and CPE. The company is a subsidiary of Shenzhen's BGI, China's largest provider of sequencing services. MGI, which wants to of...

Collaboration initiates second Roche program utilizing Icagen’s ion channel drug discovery platform Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and c...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors. The milestone pa...